

FOI Request Response information

FOI request reference:	2015/253
Date request received:	10/12/2015
Date request responded to:	24/12/2015
Category:	Pharmacy
Tags:	Biologics, biosimilars, Gastroenterology, medication

Request Detail:

Info re biologics & biosimilars

- Does your trust run a dedicated Gastroenterology infusion clinic for the treatment of patients with Infliximab [or Vedolizumab] If Yes, how frequently are they run ?
- Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below.

	Rheumatology [Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis]	Dermatology [Psoriasis]	Hidradenitis suppurativa (sometimes known as acne inversa) L73.2	Gastroenterology [Crohns / Ulcerative Colitis]
Abatacept (Orencia)				
Adalimumab (Humira)				
Apremilast (Otezla)				
Certolizumab Pegol (Cimzia)				
Etanercept (Enbrel)				
Golimumab (Simponi)				
Infliximab (Remicade)				
Infliximab biosimilar (Inflectra)				
Infliximab biosimilar (Remsima)				

Rituximab (MabThera)				
Secukinumab (Cosentyx)				
Tocilizumab (RoActemra)				
Tofacitinib [Xeljanz]				
Ustekinumab (Stelara)				
Vedolizumab (Entyvio)				

Response Detail:

The Trust response to your recent FOI request is as follows:

Q1

There are no biologic dermatology or gastroenterology therapies provided by LCFT

Q2

Where there is a blank below that indicates the treatment is not used.

	Rheumatology [Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis]	Dermatology [Psoriasis]	Hidradenitis suppurativa (sometimes known as acne inversa) L73.2	Gastroenterology [Crohns / Ulcerative Colitis]
Abatacept (Orencia)	12			
Adalimumab (Humira)	130			
Apremilast (Otezla)				
Certolizumab Pegol (Cimzia)	32			
Etanercept (Enbrel)	182			

Golimumab (Simponi)	3			
Infliximab (Remicade)	10			
Infliximab biosimilar (Inflectra)				
Infliximab biosimilar (Remsima)				
Rituximab (MabThera)	Approx. 86			
Secukinumab (Cosentyx)				
Tocilizumab (RoActemra)	8			
Tofacitinib [Xeljanz]				
Ustekinumab (Stelara)	2			
Vedolizumab (Entyvio)				